eClinical Solutions Releases Newest Version of elluminate®
eClinical Solutions, LLC, a leading provider of data management services and technologies, today announced the release of elluminate®.
eClinical Solutions, a provider of data management services and technologies, announced the release of the latest version of its end to end clinical data repository and analytics platform, elluminate®. The elluminate® platform integrates and standardizes clinical and operational data, regardless of source, to enable advanced analytics and adhoc reporting capabilities. This release enhances the ability to visualize operational data such as metrics, audit trail, and queries to support risk based monitoring and site management. The release also enhances the ability to define workflows to support advanced data integrations. Read the full text here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
